Halozyme Therapeutics Inc. (HALO)
HALO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/0001159036-26-000024-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | HALO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001159036 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.4B |
| Net income | $316.9M |
| Operating income | $469.0M |
| Net margin | 22.7% |
| Operating margin | 33.6% |
| Revenue growth | +37.6% |
| Cash | $133.8M |
| Total assets | $2.5B |
| P/E (computed) | 34.7× |
| P/S (computed) | 7.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $1.0B cash; operating cash flow $224.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 114,010,000 (2026-10-31); 117,597,000 a year earlier; 132,098,110 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $45.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $493.0M | $247.0M | $258.3M | $1.0B | $3.3B | $1.8B | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $481.0M | $229.9M | $240.9M | $163.1M | $2.1B | $1.7B | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $376.7M | $150.0M | $180.1M | $309.7M | $2.1B | $1.5B | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $451.8M | -$141.6M | $219.0M | $133.8M | $2.1B | $1.4B | 10-K 2026-02-17 |
| Q3 2025 2025-09-30 | $354.3M | $175.2M | $178.6M | $419.7M | $1.5B | $1.2B | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $325.7M | $165.2M | $99.7M | $61.9M | $1.5B | $1.2B | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $264.9M | $118.1M | $154.2M | $176.3M | $1.5B | $1.1B | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $298.0M | $137.0M | $178.5M | $115.8M | $1.5B | $1.0B | 10-K 2026-02-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2017-05-19 |
| Latest annual report | 10-K | 2026-02-17 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-03-23 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.2% |
| 1 month | -8.5% |
| 3 months | -0.4% |
| Year to date | +49.0% |
| 1 year | +40.8% |
| From 52-week high | -23.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KYMR | Kymera Therapeutics Inc. | $125.85 | -1.35% | $10.7B |
| TECH | Bio-Techne Corp | $72.79 | -0.01% | $11.4B |
| RGEN | Repligen Corporation | $162.78 | -2.99% | $10.4B |
| QGEN | Qiagen N.V. Common Shares | $49.81 | -0.16% | $10.3B |
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
| KRYS | Krystal Biotech Inc. | $297.90 | -2.40% | $8.8B |
| CGON | CG Oncology Inc. | $84.78 | +13.95% | $7.6B |
| EXEL | Exelixis Inc. | $67.10 | -2.75% | $16.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier